Hydroxyurea Dosing for Thrombocytosis
Start hydroxyurea at 500 mg daily and titrate upward based on platelet response and tolerance, with a target dose of 2 g/day (2.5 g/day if body weight >80 kg) to achieve platelet count <400 × 10⁹/L. 1
Starting Dose
The initial dose is 500 mg once daily, which should be adjusted based on individual efficacy and tolerability 1. The FDA-approved general starting dose for cytoreductive therapy is 15 mg/kg once daily 2, but in clinical practice for thrombocytosis specifically, the 500 mg daily starting point is standard.
Dose Escalation Strategy
- Titrate gradually to achieve platelet control while monitoring for toxicity
- Target therapeutic dose: 2 g/day for most patients 3, 4
- For patients >80 kg: Target dose is 2.5 g/day 4
- Assessment timepoint: Evaluate response after 3 months at therapeutic dose 3, 4
Treatment Goals
The optimal target is **platelet count <400 × 10⁹/L** 3, 4. For essential thrombocythemia specifically, European LeukemiaNet guidelines define resistance to hydroxyurea as platelet count >600 × 10⁹/L after 3 months of at least 2 g/day (or 2.5 g/day if >80 kg) 4.
Monitoring Requirements
- Weekly complete blood counts during therapy 2
- Watch for myelosuppression: dose reduction or discontinuation required if:
- Absolute neutrophil count <1.0 × 10⁹/L
- Platelet count <100 × 10⁹/L (for PV/ET) or <50 × 10⁹/L (for myelofibrosis)
- Hemoglobin <10 g/dL 4
Special Dosing Considerations
Renal impairment: Reduce dose by 50% if creatinine clearance <60 mL/min or end-stage renal disease. Start at 7.5 mg/kg once daily instead of 15 mg/kg 2.
Extreme thrombocytosis (platelets >1,500 × 10⁹/L): Higher initial doses may be warranted. One case report used 3 g/day urgently for acquired von Willebrand syndrome with successful platelet reduction within 24 hours 5. However, this represents urgent cytoreduction rather than standard initiation.
Critical Pitfalls
Age considerations: Use hydroxyurea with caution in patients <40 years old due to potential leukemogenic risk with long-term exposure 3. Consider interferon-alpha as first-line in young patients instead.
Pregnancy: Hydroxyurea is absolutely contraindicated—it is teratogenic and embryotoxic 2, 6. Verify pregnancy status before starting and ensure effective contraception (females for 6 months after therapy, males for 1 year after therapy) 2.
Anemia management: Worsening anemia occurs commonly (seen in 45% of patients in one series) and may require concomitant erythropoietin-stimulating agents or danazol 1. Correct severe anemia before initiating hydroxyurea 2.
Non-hematologic toxicity: Monitor for leg ulcers, mucocutaneous manifestations, GI symptoms, and fever—these constitute intolerance requiring therapy change 4.
When to Switch Therapy
Change to second-line agents (interferon-alpha or anagrelide) if after 3 months at adequate doses (≥2 g/day) there is:
- Persistent platelet count >600 × 10⁹/L in essential thrombocythemia 4
- Unacceptable toxicity at any dose 4
- Development of cytopenias at the lowest effective dose 4
The response duration when hydroxyurea is effective averages 13.2 months but can extend beyond 10 years 1.